US 12,728,132 B2
Inhibitors of the peptidyl-prolyl cis/trans isomerase (PIN1), combinations and uses thereof
Shizhong Ke, Boston, MA (US); Gerburg Wulf, Boston, MA (US); Xiao Zhen Zhou, Newton, MA (US); Nir London, Rehovot (IL); Wenyi Wei, Boston, MA (US); Kun Ping Lu, Newton, MA (US); Nathanael S. Gray, Stanford, CA (US); and Behnam Nabet, Boston, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); BETH ISRAEL DEACONESS MEDICAL CENTER, INC., Boston, MA (US); and YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL)
Appl. No. 18/694,557
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); BETH ISRAEL DEACONESS MEDICAL CENTER, INC., Boston, MA (US); and YEDA RESEARCH AND DEVELOPMENT CO. LTD., Rehovot (IL)
PCT Filed Sep. 23, 2022, PCT No. PCT/US2022/076950
§ 371(c)(1), (2) Date Mar. 22, 2024,
PCT Pub. No. WO2023/049851, PCT Pub. Date Mar. 30, 2023.
Claims priority of provisional application 63/248,100, filed on Sep. 24, 2021.
Prior Publication US 2025/0127783 A1, Apr. 24, 2025
Int. Cl. A61K 31/519 (2006.01); A61K 31/203 (2006.01); A61K 31/381 (2006.01); A61K 31/506 (2006.01); A61K 33/36 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/203 (2013.01); A61K 31/381 (2013.01); A61K 31/506 (2013.01); A61K 33/36 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01)] 21 Claims
 
1. A method of treating a disease or disorder mediated by dysregulated cyclin-dependent kinase 4/6 (CDK4/6) activity, in a subject in need thereof, or a method of reducing the activity of CDK4/6 in a cell, either in vivo or in vitro,
comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) inhibitors, or a pharmaceutically acceptable salt or salts thereof.